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Purpose: In Europe, 4 inhaled antibiotics (tobra-
mycin, colistimethate sodium, aztreonam, and levo-
ﬂoxacin) are currently approved for the treatment of
chronic Pseudomonas aeruginosa lung infection in
patients with cystic ﬁbrosis (CF). Levoﬂoxacin inha-
lation solution (LIS) is the most recently approved
inhaled antibiotic for adult patients with CF. A
systematic literature review and Bayesian network
meta-analysis (NMA) was conducted to compare the
relative short-term (4 weeks) and long-term (24
weeks) outcomes of these inhaled antibiotics versus
LIS.
Methods: A systematic literature search was con-
ducted on February 16, 2016, using EMBASE and
Medline via OvidSP. All randomized controlled trials
comparing any of the aforementioned inhaled anti-
biotics with 4 or 24 weeks of follow-up were eval-
uated. NMA was performed for the following
outcomes: relative and absolute percent changes from
baseline in forced expiratory volume in 1 second
(FEV1%) predicted, change in P aeruginosa sputum
density, respiratory symptoms score from the CF
questionnaire–revised, hospitalization, additional anti-
biotics use, and study withdrawal rates.
Results: Of the 685 articles identiﬁed, 7 unique
studies were included in the 4 weeks’ NMA and 9
unique studies were included in the 24 weeks’ NMA.
Aztreonam was predicted to result in the greatest] 2016numerically increase in FEV1% predicted at 4 weeks,
whereas LIS were predicted to be numerically greater
than colistimethate sodium, tobramycin inhaled sol-
ution (TIS), and tobramycin inhaled powder (TIP).
However, all of the 95% credibility intervals (CrIs) of
these comparisons included zero. At 24 weeks, none
of the treatments was signiﬁcantly more effective than
LIS. The estimates for the mean change from baseline
to 24 weeks in relative FEV1% versus LIS was –0.55
(95% CrI, –3.91 to 2.80) for TIS, –2.36 (95% CrI, –
7.32 to 2.63) for aztreonam, –2.95 (95% CrI, –10.44
to 4.51) for TIP, and –9.66 (95% CrI, –15.01 to –
4.33) for placebo. Compared with LIS, the odds ratio
for hospitalization at 24 weeks was 1.92 (95% CrI,
1.01–3.30) for TIS, 2.25 (95% CrI, 1.01–4.34) for
TIP, and 3.16 (95% CrI, 1.53–5.78) for placebo, all
statistically worse than LIS. P aeruginosa sputum
density scores, additional use of antipseudomonal
antibiotics, and study withdrawal rates were compa-
rable among all inhaled antibiotics at all times.
Implications: Based on this NMA, the analyses for
many of the outcomes did not provide signiﬁcant1
Clinical Therapeuticsevidence to indicate that the other approved inhaled
antibiotics were more effective than LIS for the treat-
ment of chronic P aeruginosa lung infection in
patients with CF. Study withdrawal rates seemed to
be comparable among these inhaled antibiotics. (Clin
Ther. 2016;]:]]]–]]]) & 2016 The Authors. Published
by Elsevier HS Journals, Inc.
Key words: cystic ﬁbrosis, levoﬂoxacin inhalation
solution, network meta-analysis.INTRODUCTION
Chronic lung infection in patients with cystic ﬁbrosis
(CF) usually involves multiple bacterial species but is
frequently dominated by Pseudomonas aeruginosa.
Chronic P aeruginosa lung infection is the primary
cause of progressive lung function decline, increased
morbidity, and mortality. Once chronic P aeruginosa
lung infection occurs, long-term maintenance therapy
with inhaled antibiotics is recommended to suppress
infection, reduce acute pulmonary exacerbations, and
preserve lung function.1,2
A variety of inhaled antibiotics in various delivery
systems have been approved for the treatment of
chronic P aeruginosa lung infection, including tobra-
mycin, aztreonam, colistimethate sodium, and (most
recently) levoﬂoxacin. The relative efﬁcacy of these
inhaled antibiotics has not been well deﬁned because
of the lack of direct comparison among these
treatments.
In 2012, Littlewood et al3 conducted a network
meta-analysis (NMA) to evaluate the relative efﬁcacy
at 4 weeks of tobramycin inhaled powder (TIP),
tobramycin inhaled solution (TIS), colistimethate so-
dium for inhalation, and aztreonam inhalation sol-
ution for the treatment of chronic P aeruginosa lung
infection in patients with CF. They included a total of
7 clinical trials that reported the following outcomes
at 4 weeks: percent change from baseline in forced
expiratory volume in 1 second (FEV1%) predicted,
P aeruginosa sputum density, and acute pulmonary
exacerbations. The investigators reported that im-
provements in efﬁcacy (as measured by changes in
FEV1% predicted at 4 weeks) were comparable
between the tobramycin preparations, colistimethate
sodium for inhalation, and aztreonam inhalation
solution.2A systematic review of the clinical effectiveness and
cost-effectiveness of colistimethate sodium for inhala-
tion and TIP for the treatment of chronic P aerugi-
nosa lung infection in CF was conducted by Tappenden
et al4 in 2013. Both colistimethate sodium for
inhalation and TIP were reportedly noninferior to TIS
as measured by predicted FEV1% in the clinical
effectiveness review. The investigators also assessed
the viability of an NMA with key study characteristic
data extracted from an additional 13 trials from 16
publications. They concluded that due to heterogeneity
of the subjects’ baseline characteristics among these
trials and the incompleteness of the evidence network,
an NMA could not be performed.
Although the 2 reviews provided some level of
evidence that these inhaled antibiotics are comparable
in efﬁcacy in the short term (4 weeks), they did not
include levoﬂoxacin inhalation solution (LIS), which
was recently approved in Europe, as a comparator.3–6
It was unclear if these inhaled antibiotics have com-
parable efﬁcacy proﬁles beyond 4 weeks. Thus, we
performed a systematic literature review (SLR) and an
NMA to achieve the following: (1) identify the clinical
evidence for the most widely used inhaled antibiotics
(tobramycin, aztreonam, and colistimethate sodium)
for the management of chronic P aeruginosa lung
infection in patients with CF; and (2) compare the
short-term (4 weeks) and long-term (24 weeks) efﬁ-
cacy of LIS versus other inhaled antibiotics in this
indication. Although safety was not assessed, study
withdrawals (including withdrawals due to adverse
events [AEs]) are described.MATERIALS AND METHODS
Systematic Literature Review
The systematic literature review was undertaken
according to the Centre for Reviews and Dissemina-
tion and the Preferred Reporting Items for Systematic
Review and Meta-analysis.7
Search Strategy and Study Selection
A systematic literature search was conducted by
using electronic databases EMBASE and Medline via
OvidSP on February 16, 2016, to identify relevant
randomized controlled trials (RCTs) of inhaled anti-
biotics meeting the following criteria: RCTs of pa-
tients with CF ≥6 years of age, previously treated with
inhaled antibiotics, diagnosed with P aeruginosaVolume ] Number ]
J.S. Elborn et al.infections, evaluating the efﬁcacy, safety, or quality of
life outcome measures of anti-pseudomonal antibiot-
ics, over a study duration of either 4 or 24 weeks. A
detailed overview of inclusion and exclusion criteria is
provided in Table I. Unpublished data from clinical
study reports (MPEX-204, MPEX-207, and MPEX-
209) held by Raptor Pharmaceuticals, Inc were also
included.8–10 The manufacturers of other inhaled
antibiotics were not contacted for unpublished data.
The list of unique titles and abstracts were screened
by 2 independent reviewers to select relevant articles
according to the predeﬁned inclusion and exclusion
criteria. Once the selection of chosen publications was
ﬁnalized, the publications were checked for any
possible linking or duplicity. Other published SLRs
identiﬁed through the search were retrieved and cross-
checked against our screening decisions to ensure
consistency.3,4
Quality Assessment
We assessed the risk of bias in these clinical trials
and evaluated the quality of evidence, by using the
Cochrane Risk of Bias Tool. RCTs included in the
review were assessed by 1 reviewer for randomization,
blinding, and adequacy of analyses. This analysis was
then reviewed by another reviewer, and disagreements
were resolved by consensus.
Data Collection and Extraction
Data were extracted into speciﬁcally designed data
extraction forms that were tested and validated on 3
randomly selected, included studies. Extracted data
included information regarding study design, patient
characteristics, details of intervention, outcomes de-
scription, results for each outcome, and study limi-
tations. Grafula 3 V2.1 (WESik Soft Haus, Moscow,
Russia) for a PC was used to extract data from the
graphs.
The outcome results were extracted (means, mean
change from baseline to ﬁnal visit, and difference of
mean change) with deviation information, such as
SEs, signiﬁcance levels, and CIs, to estimate missing
SDs wherever possible. Data for both continuous and
binary outcomes were extracted based on the number
of patients included in the analysis. Where possible,
reported ﬁndings were based on the full analysis set. If
studies reported the mean adjusted for baseline values
(eg, using analyses of covariates), these values were
also extracted.] 2016Network Meta-analysis
An NMA was performed to compare the efﬁcacy of
LIS (Quinsairs, Raptor Pharmaceuticals Europe B.V.,
Amsterdam, The Netherlands) with any methods of
inhaled delivery of tobramycin (TOBIs, Novartis Phar-
maceuticals UK, Surrey, UK; TOBITM PodhalerTM,
Novartis Europharm Ltd, Camberley, UK; Bramitobs,
Chiesi Limited, Manchester, UK), colistimethate sodium
(ColoBeathes, Forest Laboratories UK Limited, Devon,
UK; Colomycins, Forest Laboratories Limited, Devon,
UK; Promixins, Proﬁle Pharma Limited, West Sussex,
UK), and aztreonam (Caystons, Gilead Sciences Inter-
national Limited, Cambridge, UK).
The inclusion and exclusion criteria for the mixed
treatment comparison for the NMA were the same as
those stated for the SLR with the exception of
excluding studies with no estimates of mean changes
of key outcomes in the study design. Mixed treatment
comparisons were ﬁrst conducted by using data from
trials with 4 weeks of follow-up and then using data
from trials with 24 weeks of follow-up.
The following outcomes were compared across the
identiﬁed RCTs by using a mixed treatment compar-
ison network: changes from baseline to 4 weeks and
24 weeks in relative FEV1% predicted and absolute
FEV1% predicted; change from baseline to 4 weeks
and 24 weeks in P aeruginosa density; change from
baseline to 4 weeks and 24 weeks in CF question-
naire–revised (CFQ-R) respiratory symptoms score
(RSS); hospitalization; use of additional inhaled or
systemic antipseudomonal antibiotics; and study
withdrawal rates for any reason, for lack of efﬁ-
cacy, or AEs. An assessment of safety was not
performed given a lack of detailed information
across studies.
Statistical Methods
In an NMA, the efﬁcacy of a particular intervention
versus competing interventions can be obtained in the
absence of head-to-head comparisons; an indirect
treatment comparison of 2 interventions is made via
a common comparator. Bayesian NMA models were
used to simultaneously synthesize the results of the
included studies for each outcome of interest.11–14
For the continuous outcomes, a normal likelihood
distribution was used; for the binary outcomes, a
binomial likelihood was used.12,14–16 Both ﬁxed ef-
fects and random effects models were evaluated. Fixed
effects models assume 1 true treatment effect, whereas3
Table I. Patients, intervention, comparator, outcomes, study (PICOS) design inclusion and exclusion criteria.
PICOS Criteria Inclusion Exclusion
Study design Abstract selection Randomized controlled trials Cost-effectiveness analyses
Study duration Z4 wk or Z24 wk* Observational studies
Full-text selection Randomized controlled trials (full-text or abstracts) Reviews or meta-analyses†
Methodology studies or protocols
“N of 1” trials (ie, sample size of 1
patient)
Studies lasting o4 weeks
Single-arm studies
Opinions, editorials, letters
Population Abstract and full-text
selection
CF patients with chronic Pseudomonas aeruginosa infection Studies including only patients aged o6 y
Patients aged Z6 y Studies including only patients aged
o21 y
Studies that include adults and children Study including only patients with ﬁrst or
new P aeruginosa infectionMean FEV1% predicted of included patients at baseline
r70% predicted
Z70% of included patients previously treated by inhaled
antibiotics
Treatment/
intervention
Abstract and full-text
selection
Any inhaled antibiotic, at any dose, using any method of
delivery:
None
 Tobramycin (TOBIs, Novartis Pharmaceuticals UK,
Surrey, UK; TOBI Podhaler, Novartis Europharm
Ltd, Camberley, UK; Bramitobs, Chiesi Limited,
Manchester, UK)
 Colistimethate sodium (ColoBreathes, Forest
Laboratories UK Limited, Devon, UK;
Colomycins, Forest Laboratories Limited, Devon,
UK; Promixins, Proﬁle Pharma Limited, West
Sussex, UK)
 Aztreonam (Caystons, Gilead Sciences International
Limited, Cambridge, UK)
 Levoﬂoxacin (Quinsairs, Raptor Pharmaceuticals
Europe B.V., Amsterdam, The Netherlands)
None
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Table I. (continued).
PICOS Criteria Inclusion Exclusion
Comparator Abstract and full-text
selection
All listed above in treatment/intervention, as well as
placebo
Outcomes Abstract selection No selection on outcomes during the abstract screening
Full-text selection Report results for 1 of the following outcomes (for all
treatments):
Outcomes not of interest
 Relative change in FEV1% predicted
 Absolute change in FEV1% predicted
 Change in P aeruginosa density
 CFQ-R respiratory symptoms score
 Hospitalization
 Additional antibiotic use
 Withdrawal for any reason
 Withdrawal for lack of efﬁcacy
 Withdrawals for any AEs
AE ¼ adverse events; CF ¼ cystic ﬁbrosis; CFQ-R ¼ cystic ﬁbrosis questionnaire–revised; FEV1 ¼ forced expiratory volume at 1 second.
*Two separate literature searches were conducted using the same inclusion and exclusion criteria, with the exception of duration of follow-up. The ﬁrst search
included studies with Z4 weeks of follow-up, and the second search included studies with Z24 weeks of follow-up.
†Reviews and meta-analyses were excluded from data extraction because the pooled results could not be used in our analysis. However, good-quality meta-analyses
and reviews (ie, Cochrane reviews) could be used for cross-checking of references if the search did not omit any articles.
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(n =12)
(9 trials)
Records screened 
(n = 685) 
Full-text articles 
assessed for eligibility 
(n = 95) 
Sc
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en
in
g
El
ig
ib
ili
ty
Duplicates removed 
(n = 179) 
Records identified through 
database searching:
Medline and EMBASE via OvidSP
(N = 864)
In
cl
ud
ed
Full-text articles excluded: (n = 86)
Study design not of interest (n= 57); patient 
population not of interest (n= 9); intervention 
not of interest (n = 10); comparator not of 
interest (n = 1); outcomes not of interest (n= 8) 
language (n= 0); duplicate (n= 1)
Trial reports provided 
by manufacturer (n= 3)
Full-text articles excluded: (n = 87)
Not relevant study design (n= 61); not relevant 
population (n= 7); not relevant intervention (n=
9); not relevant comparator (n= 1); outcomes 
not of interest (n = 8); duplicate (n= 1)
4 weeks
Trial reports provided by 
manufacturer (n= 1)
24 weeks
Articles selected 
(n =9)
(7 trials)
Figure 1. Flow diagram of the screening, identifying, and selecting of studies with study duration of 4 and 24
weeks for network meta-analysis of comparison of inhaled antibiotics for the treatment of chronic
Pseudomonas aeruginosa lung infection in patients with cystic fibrosis. Please see Table 2 for
additional information on MPEX studies.
Clinical Therapeuticsrandom effects models allow for different true treat-
ment effects across studies, thus taking into account
the heterogeneity in relative treatment effects. The
deviance information criterion was used to compare
the models, which provides a measure of model ﬁt that
penalizes model complexity accordingly.17 All models
were based on the NICE Decision Support Unit6research. All WinBUGS codes for continuous and
binary outcomes were based on the NICE Decision
Support Unit TSDS document.7 The analyses were
performed by using WinBUGS 1.4.1 statistical
software.18
The results of the NMA are presented in terms of
point estimates for the relative treatment effects andVolume ] Number ]
Table II. Characteristics of the studies included in the network meta-analysis.
Author/Year
Intervention (Upper, Study
Drug; Lower, Comparator)
Double-blind/
Open-label
Patient
Population
No. of
Randomized
Patients Trial Length Treatment Schedule
Ramsey et al,28
1999
Tobramycin nebulizer
solution 300 mg
Double-blind Z6 y 520 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentPlacebo
Chuchalin et al,29
2007
Tobramycin nebulizer
solution 300 mg BID
Double-blind Z6 y 247 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentPlacebo
Hodson et al,20
2002
Tobramycin nebulizer
solution 300 mg BID
Open-label Z6 y 126 8 wk Intervention and comparator: BID for
4 weeks followed by 4 wk of follow-
upColistimethate sodium
nebulizer solution 80 mg
BID
McCoy et al,21
2008
Aztreonam nebulizer
solution 75 mg BID
Double-blind Z6 y 246 12 wk Intervention and comparator: BID or
TID for 4 wk followed by 8 wk of
follow-upAztreonam nebulizer
solution 75 mg TID
Placebo
Nasr et al,22 2010 Tobramycin nebulizer
solution 300 mg BID
Double-blind Z6 y 32 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentPlacebo
Konstan et al,23
2011
Tobramycin inhaler powder
112 mg BID
Open-label Z6 y 553 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentGeller et al,24 2014 Tobramycin nebulizer
solution 300 mg BID
Schuster et al,25
2013
Colistimethate sodium
inhaler powder 1,662,500
IU BID
Open-label Z6 y 380 24 wk Intervention: continuous treatment
Tobramycin nebulizer
solution 300 mg BID
Comparator: 3 cycles of 28 d on
treatment followed by 28 d off
treatment
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Table II. (continued).
Author/Year
Intervention (Upper, Study
Drug; Lower, Comparator)
Double-blind/
Open-label
Patient
Population
No. of
Randomized
Patients Trial Length Treatment Schedule
Assael et al,26 2013 Aztreonam nebulizer
solution 75 mg TID
Open-label Z6 y 273 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentTobramycin nebulizer
solution 300 mg BID
MPEX-204
report9,27
Levoﬂoxacin nebulizer
solution 120 mg QD
Double-blind Z16 y 151 8 wk Intervention and comparator: 1 cycle
of 28 d on treatment followed by 28
d off treatmentLevoﬂoxacin nebulizer
solution 240 mg QD
Levoﬂoxacin nebulizer
solution 240 mg BID
Placebo
MPEX-207
report10,30
Levoﬂoxacin nebulizer
solution 240 mg BID
Double-blind Z12 330 8 wk Intervention and comparator: 1 cycle
of 28 d on treatment followed by 28
d off treatmentPlacebo
MPEX-209
report6,8
Levoﬂoxacin nebulizer
solution 240 mg BID
Open-label Z12 y 282 24 wk Intervention and comparator: 3 cycles
of 28 d on treatment followed by 28
d off treatmentTobramycin nebulizer
solution 300 mg BID
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J.S. Elborn et al.the 95% credible intervals (95% CrIs). The proba-
bility that each treatment is best is also presented;
this probability was calculated based on the propor-
tion of Markov chain Monte Carlo cycles in which
a speciﬁc treatment ranks ﬁrst out of the total
(in which the ranking is based on the treatment
effect size).19
Analysis Outputs
A network diagram representing all direct com-
parisons between treatments included in the analysis
was produced for each outcome of interest. Results
are presented with summary statistics, including
estimates for the mean change in the number of
events for the efﬁcacy outcomes and the odds ratio
(OR) estimates for the dichotomous outcomes. Mean
values, SEs, and 95% CrIs are reported for differ-
ences in changes from baseline to end point between
LIS and the other treatments. A difference in mean
change was considered as statistically signiﬁcant
when the associated 95% CrIs did not include zero.
Relative risk (RR) and OR values with correspond-
ing 95% CrIs for other parameters were reported as
appropriate. An OR was considered statistically
signiﬁcant when the associated 95% CrI did not
include unity. Additional outputs included mean
rank for each treatment, probability of being the
best treatment, and surface under the cumulative
ranking line (SUCRA) for each treatment. SUCRA
will be 1 when a treatment is certain of being
the best or 0 when a treatment is certain to be
the worst.RESULTS
Systematic Literature Review
Study Selection
Figure 1 presents the Preferred Reporting Items for
Systematic Review and Meta-analysis ﬂow diagrams
for the study selection process for SLRs limited to
those with study duration of 4 weeks and those with
study duration of 24 weeks.
Study Characteristics
The study characteristics of the included studies are
presented in Table II. Nine RCTs (12 publications)
with 4 weeks of follow-up were eligible for review,
and relevant outcome data were extracted.6,8–10,20–27
Five trials were open-label,6,8,20,23–26 and 1 of the] 2016included trials also published a post hoc subgroup
analysis to assess the effect of TIP and TIS in children,
adolescents, and adults24 as well as the main
analysis.23
Seven RCTs (9 publications) with 24 weeks of
follow-up were eligible for review, and the relevant
outcome data were extracted.6,8,22–26,28,29 Four trials
were open-label,6,8,23–26 and 1 of the included trials
also published a post hoc subgroup analysis to assess
the effect of TIP and TIS in children, adolescents, and
adults24 as well as the main analysis.23
A risk-of-bias assessment conducted by using the
tool recommended by the Cochrane Collaboration
revealed that a high risk of bias was suspected due to
the large number of studies with an open-label design
(Table III). The risk of bias could not be fully assessed
(in particular, allocation concealment and detection
bias) because the full methodology was not detailed in
every publication.
Comparators
For the trials with a study duration of 4 weeks, 6
(66.7%) of the 9 trials included TIS as a treatment
comparator and 4 (44.4%) of the 9 trials included
placebo as a treatment comparator. LIS was assessed
in 3 trials (33.3%), aztreonam in 2 trials (22.2%),
colistimethate sodium inhaler powder in 1 trial
(11.1%), and colistimethate sodium inhaler solution
in 1 trial (11.1%). For the trials with study duration
of 24 weeks, all trials included TIS as the treatment
comparator.
Patient Characteristics
Table IV presents the baseline characteristics
(intervention, age, sex, body mass index [BMI],
FEV1% predicted, previous inhaled antibiotic use,
and concomitant treatments) of these patients in the
included trials. Due to the differences in inclusion
criteria among the studies and the time period that
these studies were conducted, there are notable
differences in patient characteristics. The patients in
the trial reported by Chuchalin et al29 and Nasr et al22
had a lower mean age compared with the other trials.
Because age and FEV1% predicted status are thought
to have an inverse correlation, it might be expected
that the patients in these trials could be earlier in their
stage of chronic P aeruginosa infection than those in
the other trials. The baseline FEV1% predicted value
reported by Nasr et al was much higher than that9
Table III. Summary of risk bias assessment of identified randomized controlled trials.
Author/Year
1/Random
Sequence
Generation
2/Allocation
Concealment
3/Blinding of
Participants
and Personnel
4/Detection
Bias, Patient-
Reported
Outcomes
5/Detection
Bias,
Mortality
6/Attrition Bias,
Short-Term
Outcomes
7/Attrition
Bias, Longer
Term Outcomes
8/Selective
Reporting
Ramsey et al,28 1999 √ ? √ ? ? √ √ √
Chuchalin et al,29 √ ? √ ? ? √ √ √
Hodson et al,20 √ ?    √ √ √
McCoy et al,21 2008 √ ?  √ ? √ √ √
Nasr et al,22 2010 √ √ √ ? √ √ √ √
Konstan et al,23 2011 √ ?    √ √ √
Geller et al,24 2014
Schuster et al,25 2013 √ ?    √ √ √
Assael et al,26 2013 √ ?    ? ? √
MPEX-204 report9 √ ? √ ? ? √ √ √
Geller et al,27 2011
MPEX-207 report,10
Flume et al,30 2016
√ √ √ ? √ √ √ √
MPEX-209 report,8
Elborn et al,6 2015
√ √    √ √ √
Check mark indicates low risk; question mark indicates unclear risk; and cross mark indicates high risk.
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Table IV. Baseline characteristics of patients. Values are given as mean (SD) unless otherwise indicated.
Study Intervention Age, y Male/Total (%) BMI, kg/m2
FEV1%
Predicted Previous Antibiotic Use Concomitant Treatment
Ramsey et al,28 1999 Tobramycin nebulizer
solution 300 mg BID
20.8 (9.50) 149/258 (58%) NR 49.9 (15.5) NR Dornase alfa: n ¼ 198 (77%)
Placebo 20.6 (10.00) 132/262 (50%) NR 51.2 (16.8) NR Dornase alfa: n ¼ 204 (78%)
Chuchalin et al,29 2007 Tobramycin nebulizer
solution 300 mg BID
14.8 (5.70) 89/161 (55.3%) 16.9 (2.8) 60.7 (14.8) NR Dornase alfa: 88%
Placebo 14.7 (6.60) 46/84 (54.8%) 16.8 (2.9) 63.6 (15) NR Dornase alfa: 88%
Hodson et al,20 Tobramycin nebulizer
solution 300 mg BID
21.3 (9.60) 20/53 (37.7%) NR 55.4 (22.9) Tobramycin use in 6 mo:
n ¼ 25 (47.1%)
Other: n ¼ 36 (67.9%)
Colistin use in 6 mo: n ¼ 45
(84.9%)
Other in previous 6 mo: n ¼ 48
(90.6%)
Colistimethate sodium
nebulizer solution 80 mg
BID
20.1 (9.40) 32/62 (51.6%) NR 59.4 (22.6) Tobramycin use in 6 mo: n ¼ 29
(46.7%)
Other: n ¼ 34 (45.2%)
Colistin use in 6 mo: n ¼ 51
(82.2%)
Other in previous 6 mo: n ¼ 50
(80.6%)
McCoy et al,21 2008 Aztreonam nebulizer
solution 75 mg BID
26.5 (NR) 38/69 (55.1%) 20.9 (3.3) 56.3 (14.8) No. of previous antibiotic
courses in previous year:
5.46
Azithromycin use: 69.6%
Dornase alfa: 81.2%
Hypertonic saline: 8.7%
Aztreonam nebulizer
solution 75 mg TID
24.1 (NR) 38/66 (57.6%) 21 (4.5) 55.4 (16.3) No. of previous antibiotic
courses in previous year:
5.26
Azithromycin use: 74.2%
Dornase alfa: 84.8%
Hypertonic saline: 12.1%
Aztreonam pooled 25.3 (NR) 76/135 (56.3%) 20.9 (3.9) 55.8 (15.5) No. of previous antibiotic
courses in previous year:
5.36
Azithromycin use: 71.9%
Dornase alfa: 83%
Hypertonic saline: 10.4%
Placebo 27.9 (NR) 45/76 (59.2%) 21.7 (3) 53.9 (15.3) No. of previous antibiotic
courses in previous year:
5.26
Azithromycin use: 65.8%
Dornase alfa: 89.5%
Hypertonic saline: 11.8%
Nasr et al,22 2010 Tobramycin nebulizer
solution 300 mg BID
11.81 (7.46) 6/16 (37.5%) NR 95.73 (17.21) NR NR
Placebo 15.86 (7.25) 6/16 (37.5%) NR 83.71 (21.07) NR NR
Konstan et al,23 2011
(General) Geller
et al,24
2014 (aged Z20 y)
General population
Tobramycin inhaler powder
112 mg BID
26 (11.4) 171/308 (55.5%) 20.7 (4) 53 (14.2) Tobramycin use: 82.1% NR
Antipseudomonal antibiotic use
(last use before ﬁrst dose):
 1 month: n ¼ 78 (25.3%)
 41–3 mo: n ¼ 171 (55.5%)
 43–6 mo: n ¼ 33 (10.7%)
 46 mo: n ¼ 11 (3.6%)
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Table IV. (continued).
Study Intervention Age, y Male/Total (%) BMI, kg/m2
FEV1%
Predicted Previous Antibiotic Use Concomitant Treatment
Tobramycin nebulizer
solution 300 mg BID
25 (10.2) 115/209 (55%) 20.4 (3.5) 53 (SD 15.9) Tobramycin use: 82.3% NR
Antipseudomonal antibiotic use
(last use before ﬁrst dose):
 1 month: n ¼ 46 (22%)
 41–3 mo: n ¼ 112 (53.6%)
 43–6 mo: n ¼ 24 (11.5%)
 46 mo: n ¼ 9 (4.3%)
Aged Z20 y
Tobramycin inhaler powder
112 mg BID
NR (NR) 126/214 (58.9%) NR 50.7 (13.8) Tobramycin use: n ¼ 176
(82.2%)
NR
Antipseudomonal antibiotic
use: n ¼ 200 (93.5%)
Tobramycin nebulizer
solution 300 mg BID
NR (NR) 79/143 (55.2%) NR (NR) 52 (SD 15.7) Tobramycin use: n ¼ 113 (79%) NR
Antipseudomonal antibiotic
use: n ¼ 128 (89.5%)
Schuster et al,25 2013 Colistimethate sodium
inhaler powder
1,662,500 IU BID
21.3 (9.72) 103/183 (56.3%) 18.67 (3.396) N/A (SD N/A) NR NR
Tobramycin nebulizer
solution 300 mg BID
20.9 (9.30) 101/191 (52.9%) 18.46 (3.584) NA NR NR
Assael et al,26 2013 Aztreonam nebulizer
solution 75 mg TID
25.8 (9.10) 68/136 (50%) 20.2 (3) 52.3 (15.6) Tobramycin use in previous
year:
 o84 d: n ¼ 21 (15.4%)
 Z84 d: n ¼ 115 (84.6%)
 Colistin use in previous year:
n ¼ 50 (36.8%)
Azithromycin use at baseline: n
¼ 85 (62.5%)
Dornase alfa use at baseline: n
¼ 92 (67.6%)
Hypertonic saline use at
baseline: n ¼ 44 (32.4%)
Tobramycin nebulizer
solution 300 mg BID
25.1 (9.00) 66/132 (50%) 20.5 (2.8) 52.2 (14.6) Tobramycin use in previous
year:
 o84 d: n ¼ 19 (14.4%)
 Z84 d: n ¼ 113 (85.6%)
 Colistin use in previous year:
n ¼ 53 (40.2%)
Azithromycin use at baseline: n
¼ 89 (67.4%)
Dornase alfa use at baseline: n
¼ 91 (68.9%)
Hypertonic saline use at
baseline: n ¼ 46 (34.8%)
MPEX-204 report9
Geller et al,27 2011
Levoﬂoxacin nebulizer
solution 120 mg QD
28 (6.90) 20/38 (52.6%) 21.2 (3.4) 52.9 (17.68) No. of previous antibiotic
courses in previous year: 4.5
(1.6)
Azithromycin use: n ¼ 29
(76.3%)
Dornase alfa use: n ¼ 26
(68.4%)
Hypertonic saline use: n ¼ 13
(34.2%)
Salbutamol use: n ¼ 29 (76.3%)
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Table IV. (continued).
Study Intervention Age, y Male/Total (%) BMI, kg/m2
FEV1%
Predicted Previous Antibiotic Use Concomitant Treatment
Levoﬂoxacin nebulizer
solution 240 mg QD
27.5 (9.10) 21/37 (56.8%) 20.9 (3.3) 55.4 (14.41) No. of previous antibiotic
courses in previous year: 4.8
(1.7)
Azithromycin use: n ¼ 26
(70.3%)
Dornase alfa use: n ¼ 32
(86.5%)
Hypertonic saline use: n ¼ 13
(35.1%)
Salbutamol use: n ¼ 25 (67.6%)
Levoﬂoxacin nebulizer
solution 240 mg BID
29.2 (10.00) 25/39 (64.1%) 21.8 (2.6) 48.79 (15.154) No. of previous antibiotic
courses in previous year: 4.8
(1.5)
Azithromycin use: n ¼ 32
(82.1%)
Dornase alfa use: n ¼ 29
(74.4%)
Hypertonic saline use: n ¼ 22
(56.4%)
Salbutamol use: n ¼ 23 (59%)
Placebo 30.1 (9.90) 19/37 (51.4%) 21 (3.4) 52.38 (13.417) No. of previous antibiotic
courses in previous year: 5.4
(2.3)
Azithromycin use: n ¼ 25
(67.6%)
Dornase alfa use: n ¼ 31
(83.8%)
Hypertonic saline use: n ¼ 22
(59.5%)
Salbutamol use: n ¼ 25 (67.6%)
MPEX-207 report10
Flume et al,30 2016
Levoﬂoxacin nebulizer
solution 240 mg BID
29.4 (10.33) 115/220 (52.3%) 22.5 (3.96) 56.53 (15.748) No. of previous antibiotic
courses in previous year: 5.9
(2.65)
NR
Placebo 28.8 (10.94) 63/110 (57.3%) 22.1 (3.79) 56.32 (15.906) No. of previous antibiotic
courses in previous year: 6.0
(2.77)
NR
MPEX-209 report8
Elborn et al,6 2015
Levoﬂoxacin nebulizer
solution 240 mg BID
28.1 (8.96) 103/189 (54.5%) 21.8 (3.57) 54.78 (17.022) No. of previous antibiotic
courses in previous year: 6.0
(2.83)
NR
Tobramycin nebulizer
solution 300 mg BID
28.8 (10.94) 56/93 (60.2%) 21.5 (3.30) 53.2 (15.7) No. of previous antibiotic
courses in previous year: 6.0
(2.79)
NR
BMI ¼ body mass index; FEV1 ¼ forced expiratory volume in 1 second; NA ¼ not available; NR ¼ not reported
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Tobramycin 
(TIS)
Levofloxacin
Placebo
Tobramycin 
(TIP)
Aztreonam
Elborn et al,6 2015 
(MPEX-209)
Ramsey et al,28 1999
(EAGER trial)
FEV1: Forced Expiratory Volume in 1 second; 
TIP: Tobramycin inhalation powder; TIS: Tobramycin inhalation solution.
FEV1: Forced Expiratory Volume in 1 second; 
TIP: Tobramycin inhalation powder; TIS: Tobramycin inhalation solution. 
Elborn et al,6 2015 (MPEX-209)
Assael et al,26
2013
Assael et al,26
2013
Konstan et al,23 2011
Konstan et al,23 2011
(EAGER)
Hodson et al,20 2002
MPEX-207
MPEX-204
Levofloxacin Placebo
Tobramycin
(TIS)Axtreonam
Tobramycin
(TIP)
Colistimethate
sodium
A
B
Figure 2. Network diagram of direct compari-
sons for relative forced expiratory
volume in 1 second percent predicted
change from (A) baseline to 4 weeks
and (B) baseline to 24 weeks. Forest
plots for the mean change from (C)
baseline to 4 weeks and (D) baseline
to 24 weeks in relative forced expira-
tory volume in 1 second percent pre-
dicted change versus levofloxacin. The
error bar indicates the 95% credibility
intervals of the estimate. EAGER ¼
Establish a New Gold Standard
for Efficacy and Safety With Tobramy-
cin in Cystic Fibrosis; TIP ¼ tobramy-
cin inhaled powder; TIS ¼ tobramycin
inhaled solution.
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14from other included trials. BMI at baseline was not
reported in 3 trials20,22,28 or in the adult population of
the EAGER (Establish a New Gold Standard for
Efﬁcacy and Safety With Tobramycin in Cystic Fib-
rosis) trial.23 The BMI values reported by Chuchalin
et al were slightly lower than in other trials.
Concomitant medication use could not be
compared among the trials because few data were
reported. When reported, dornase alfa was the most
commonly reported concomitant medication. Subjects
in the MPEX-204, MPEX-207, and MPEX-209 trial
had all used inhaled antimicrobials in the year before
study participation.8–10 Similarly, most of the patients
in the EAGER trial23 and in the trial reported by
Assael et al26 were previously exposed to inhaled
tobramycin. The improvement in FEV1% predicted
from baseline to the end of the treatment cycle by
tobramycin has been documented to peak in the ﬁrst
cycle of treatment, with the effect becoming
attenuated over time with repeated treatment.28
Thus, an attenuated effect on the improvement in
FEV1% predicted in treatment-experienced patients in
these trials may be expected given that the maximal
effect on FEV1% predicted may have already occurred
before starting the trial. Four trials did not report the
previous antibiotics use rate.22,25,28,29
Given that age, BMI, concomitant medications,
prior exposure to antipseudomonal antibiotics, and
FEV1% predicted all have prognostic value in CF, it is
difﬁcult to determine whether these study populations
are comparable in terms of overall health and propen-
sity to beneﬁt from antipseudomonal treatments.
These factors should be taken into consideration when
making comparisons across studies.NMA Results
For NMA using trials with 4 weeks of follow-up,
both ﬁxed effects and random effects models were
performed; for all outcomes, a random effects model
was chosen due to better ﬁt in terms of deviance (DIC
value). Due to the small number of trials with 24
weeks of follow-up and only 1 trial per comparison
except for TIS and placebo comparison in the study
withdrawal rate comparisons, only ﬁxed effect models
were used for all of the outcomes.Volume ] Number ]
The error bar indicates the 95% Crl of the estimate. FEV1: Forced Expiratory Volume in 1 second; 
TID: Three times a day; TIP: Tobramycin inhalation powder; TIS: Tobramycin inhalation solution.
The error bar indicates the 95% Crl of the estimate. FEV1: Forced Expiratory Volume in 1 second; 
TID: Three times a day; TIP: Tobramycin inhalation powder; TIS: Tobramycin inhalation solution.
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FEV1: Forced Expiratory Volume in 1 second; TIS: Tobramycin inhalation solution
FEV1: Forced Expiratory Volume in 1 second; TIS: Tobramycin inhalation solution
Levofloxacin Placebo
Tobramycin
(TIS)
MPEX-204
Elborn et al,6 2015 (MPEX-209)
MPEX-207
Schuster et al,25 2013
sodiumAztrenonam
Colistimethate
(Freedom)Assael et al,26 2013
Elborn et al,6 2015 (MPEX-209) 
Chuchalin et al,29 2007Assael et al,26 2013
Schuster et al,25 2013
Levofloxacin
Aztrenonam Tobramycin(TIS)
sodium
Colistimethate
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Figure 3. Network diagram of direct compari-
sons for absolute forced expiratory
volume in 1 second percent predicted
change from (A) baseline to 4 weeks
and (B) baseline to 24 weeks. (C)
Forest plot for the mean change in
absolute forced expiratory volume in 1
second percent predicted change from
(C) baseline to 4 weeks and (D) base-
line to 24 weeks. The error bar indi-
cates the 95% credibility intervals of
the estimate. TIS ¼ tobramycin in-
haled solution.
Clinical TherapeuticsRelative FEV1% Predicted Change From Baseline
to 4 Weeks and Baseline to 24 Weeks
The network diagram for the relative FEV1%
predicted change from baseline to 4 weeks and base-
line to 24 weeks is shown in Figures 2A and 2B,
respectively.
The difference in mean change from baseline in
relative FEV1% predicted at 4 weeks compared with
LIS is given in Figure 2C. The mean change from16baseline in relative FEV1% predicted for LIS was –5.28
(95% Crl, –11.55 to 0.13) versus placebo, but the 95%
Crl included zero. A similar trend was also observed
compared with TIS, TIP, colistimethate sodium, and
aztreonam. Aztreonam 75 mg TID had the highest
probability of being the best treatment (83.8%), with
a SUCRA value of 0.951, followed by LIS with a
9.7% probability of being the best treatment, with a
SUCRA value of 0.682.
The difference in mean change from baseline in
relative FEV1% at 24 weeks compared with LIS is
given in Figure 2D. The effect of LIS was signiﬁcantly
better than placebo, with a mean change of placebo
versus LIS of –9.66 (95% CrI, –15.01 to –4.33). Other
treatments—including TIS (–0.55 [95% Crl, –3.91 to
2.80]), TIP (–2.95 [95% Crl, –10.44 to 4.51]), and
aztreonam (–2.36 [95% Crl, –7.32 to 2.63])—were
not better compared with LIS, as their respective 95%
CrIs all included zero. At 24 weeks, LIS had the
highest probability of being the best treatment
(51.3%), with a SUCRA value of 0.807, followed by
TIS with a 23.6% probability of being the best
treatment, with a SUCRA value of 0.741.
Absolute FEV1% Predicted Change From Baseline
to 4 Weeks and Baseline to 24 Weeks
The network diagram for the absolute FEV1%
predicted change from baseline to 4 weeks and to 24
weeks is shown in Figures 3A and 3B, respectively.
The difference in mean change from baseline in
absolute FEV1% predicted at 4 weeks compared with
LIS is given in Figure 3C. The effect of LIS in mean
change from baseline in absolute FEV1% predicted
was –2.68 (95% CrI, –7.49 to 1.76) versus placebo,
but the 95% Crls included zero. This trend was also
observed when LIS was compared with TIS (–1.04
[95% Crl, –7.39 to 5.29], colistimethate sodium
(–2.46 [95% Crl, –11.44 to 6.51]), and aztreonam
(2.24 [95% Crl, –6.94 to 11.44]). Aztreonam 75 mg
TID had the highest probability of being the best
treatment (67.4%), with a SUCRA value of 0.841,
followed by LIS with a 20.2% probability of being the
best treatment, with a SUCRA value of 0.656.
The difference in mean change from baseline in
absolute FEV1% predicted at 24 weeks compared
with LIS is given in Figure 3D. The effect of LIS was
signiﬁcantly better than placebo with the mean change
of placebo versus LIS of –6.43 (95% CrI, –8.84
to –4.02). Aztreonam (–0.65 [95% Crl, –3.12 toVolume ] Number ]
The error bar indicates the 95% Crl of the estimate. FEV1: Forced Expiratory Volume in 1 second; TID: Three times a 
day; TIS: Tobramycin inhalation solution.
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Table V. Estimates for mean change from baseline to 4 and 24 weeks in Pseudomonas aeruginosa sputum
density versus levofloxacin nebulizer solution.
Variable Mean Change SE 95% CrI
4 wk follow-up
Tobramycin (TIS) –0.150 0.260 –0.659 to 0.358
Tobramycin (TIP) –0.610 0.485 –1.562 to 0.336
Aztreonam 75 mg BID –0.076 0.309 –0.682 to 0.531
Aztreonam 75 mg TID –0.095 0.269 –0.622 to 0.433
Colistimethate sodium nebulizer 0.111 0.400 –0.672 to 0.894
Placebo 0.643 0.170 0.309 to 0.977
24 wk follow-up
Tobramycin (TIS) –0.180 0.260 –0.688 to 0.329
Tobramycin (TIP) –0.589 0.418 –1.41 to 0.231
Placebo 0.221 0.297 –0.36 to 0.802
CrI ¼ credibility interval; TIP ¼ tobramycin inhaled powder; TIS ¼ tobramycin inhaled solution.
Clinical Therapeutics1.82]), colistimethate sodium (–1.49 [95% Crl, –3.69
to 0.70]), and TIS (0.28 [95% CrI, –1.36 to 1.92])
were all similar compared with LIS. TIS had the
highest probability of being the best treatment
(52.5%), with a SUCRA value of 0.865, followed by
LIS with a 34.2% probability of being the best
treatment, with a SUCRA value of 0.744.P aeruginosa Sputum Density Change From
Baseline to 4 Weeks and Baseline to 24 Weeks
The differences in mean change from baseline in P
aeruginosa sputum density compared with LIS at 4
and 24 weeks are shown in Table V. At 4 weeks, the
effect of LIS was signiﬁcantly better than placebo,
with a mean change of placebo versus LIS of 0.64
log10 CFU/g sputum (95% CrI, 0.31–0.98). None of
the antibiotics were noted to be better or worse than
LIS. At 4 weeks, TIP had the highest probability of
being the best treatment (74.3%), with a SUCRA
value of 0.896, followed by aztreonam 75 mg BID
with a 9.4% probability of being the best treatment,
with a SUCRA value of 0.549.
At 24 weeks, the effect of LIS was similar to
placebo with a mean change of placebo versus LIS
of 0.22 log10 CFU/g sputum (95% CrI, –0.36 to 0.80).
LIS seemed comparable to TIP (–0.59 [95% Crl, –1.41
to 0.23]) and TIS (–0.18 [95% Crl, –0.69 to 0.33]).
Consistent with the 4 weeks’ analysis, TIP had the18highest probability of being the best treatment (87%),
with a SUCRA value of 0.935, followed by TIS with a
7.9% probability of being the best treatment, with a
SUCRA value of 0.619.CFQ-R RSS Change From Baseline to 4 and
Baseline to 24 Weeks
The change in CFQ-R RSS from baseline to 4
weeks was reported in 5 trials.8–10,21,26 Mixed treat-
ment comparisons with ﬁxed effect model revealed
that the effect of LIS (–1.07 [95% CrI, –4.00 to 1.87]),
TIS (–3.11 [95% CrI, –6.65 to 0.42]), and aztreonam
75 mg BID (4.66 [95% CrI, –0.21 to 9.54]) was not
different from placebo in reducing symptoms as
measured by using the CFQ-R RSS. Only aztreonam
75 mg TID, having a mean change of 2.60 (95% CrI,
–1.75–6.95), was likely to have a better improvement
in CFQ-R RSS compared with LIS. The aztreonam 75
mg BID regimen had the highest probability of being
the best treatment in improving symptoms (81.3%),
with a SUCRA value of 0.947, followed by aztreonam
75 mg TID with a 17.0% probability of being the best
treatment, with a SUCRA value of 0.753.
The change in CFQ-R RSS from baseline to 24
weeks was reported in only 1 trial comparing LIS with
TIS.8 In this study, although not statistically
signiﬁcant, a favorable change in the CFQ-R RSS
score (mean [SE]) was observed in the LIS-treatedVolume ] Number ]
J.S. Elborn et al.patients (2.85 [1.32]) compared with the TIS-treated
patients (–0.07 [1.76]).
Hospitalization
Hospitalization after 4 weeks of follow-up was
reported in only 2 trials.10,21 An indirect comparison
was conducted instead of NMA due to the insufﬁcient
number of trials available. The use of aztreonam 75
mg BID (RR, 1.66 [95% CrI, 0.08–34.30])
and aztreonam 75 mg TID (RR, 0.96 [95% CrI,
0.05–18.06]) was associated with similar risk of
hospitalization compared with LIS.
For trials with 24 weeks of follow-up, hospital-
ization was reported in 4 trials.8,23,28,29 Patients treated
with LIS had a statistically signiﬁcantly lower proba-
bility of hospitalization than those receiving placebo
(OR, 3.16 [95% CrI, 1.53–5.78]), TIP (OR, 2.25
[95% CrI, 1.01–4.34]), or TIS (OR, 1.92 [95% CrI,
1.01–3.30]). LIS was associated with the lowest risk of
hospitalization with a 96.5% of probability of being
the best treatment, with a SUCRA value of 0.984,
followed by TIP with a 1.8% probability of being the
best treatment, with a SUCRA value of 0.399.
Additional Antibiotics Use
Additional antibiotics use, deﬁned as the need for
additional inhaled or systemic antipseudomonal anti-
biotics, was reported in 5 trials8–10,21,26 at 4 weeks.
Compared with LIS, the use of TIS was associated
with a statistically signiﬁcantly higher need for addi-
tional antibiotics (OR, 2.19 [95% CrI, 1.03–4.08]). A
similar nonsigniﬁcant trend was also observed when
LIS was compared with placebo (OR, 1.04 [95% CrI,
0.56–1.76]). Aztreonam use was associated with a
similar probability of additional antibiotics use than
LIS (OR, 0.72 [95% CrI, 0.20–1.83]). Aztreonam was
associated with the lowest need for additional anti-
biotics and had a 73.3% probability of being the best
treatment, with a SUCRA value of 0.859, followed by
placebo with a 16.9% probability of being the best
treatment, with a SUCRA value of 0.555.
Among the trials with a study duration of
24 weeks, additional antibiotics use was reported in 5
trials.8,23,26,28,29 Compared with LIS, the use of placebo
(OR, 2.86 [95% CrI, 1.49–5.03]) and TIP (OR, 2.57
[95% CrI, 1.28–4.65]) was associated with a statisti-
cally signiﬁcant higher probability of additional anti-
biotics use. A similar nonsigniﬁcant trend was also
observed when LIS was compared with TIS (OR, 1.63] 2016[95% CrI, 0.93–2.70]). Aztreonam use was associated
with a similar probability of additional antibiotics use
compared with LIS (OR, 0.76 [95% CrI, 0.35–1.47]).
Aztreonam was associated with the lowest need for
additional antibiotics and had an 82% probability of
being the best treatment, with a SUCRA value of 0.955,
followed by LIS with an 18% probability of being the
best treatment, with a SUCRA value of 0.782.
Study Withdrawal Rate
Study withdrawal rates (categorized as study with-
drawal due to any reason, lack of efﬁcacy, or AEs)
were summarized. The speciﬁc AEs leading to study
withdrawal were not able to be assessed due to limited
information provided in the selected studies.
Study withdrawal was reported in 3 trials with 4
weeks of follow-up.9,10,20 A direct comparison was
conducted instead of the NMA due to insufﬁcient
number of trials available. The RR for the occurrence
of withdrawal for any reason in patients treated with
placebo compared with LIS was 0.416 (95% CI,
0.111–1.557). Withdrawal rates due to lack of efﬁ-
cacy was not reported in any of the studies with 4
weeks’ follow-up. As for withdrawal due to AEs, a
direct comparison was conducted instead of the NMA
due to insufﬁcient number of trials available. The RR
for the occurrence of withdrawal due to AEs in
patients treated with LIS compared with placebo
was 0.76 (95% CI, 0.18–3.2).
Rates of withdrawal for any reason were reported in
all of the trials with 24 weeks of follow-up. However,
study withdrawal rates varied substantially among the
studies. NMA showed that, compared with LIS, coli-
stimethate sodium (OR, 1.65 [95% CrI, 0.53–3.90]),
TIP (OR, 1.58 [95% CrI, 0.56–3.47]), aztreonam (OR,
0.51 [95% CrI, 0.15–1.27]), and TIS (OR, 0.92 [95%
CrI, 0.37–1.85]) were all associated with a similar risk
for study withdrawal for any reason. Aztreonam was
associated with the lowest risk of withdrawal for any
reason with a 91.2% probability of being the best
treatment, with a SUCRA value of 0.976, followed by
LIS with a 6.1% probability of being the best treat-
ment, with a SUCRA value of 0.519.
An NMA was not performed for rates of with-
drawal due to lack of efﬁcacy because only 1 study
with 24 weeks of follow-up reported this outcome.
The rates of withdrawal from the study for any AEs
were reported in 5 trials. NMA showed that compared
with LIS, risk of withdrawal due to AEs were19
Clinical Therapeuticscomparable with aztreonam (OR, 0.29 [95% CrI,
0.003–1.59]), TIS (OR, 0.40 [95% CrI, 0.01–1.72]),
and TIP (OR, 0.72 [95% CrI, 0.01–3.26] as well as
colistimethate sodium (OR, 4.10 [95% CrI, 0.05–
21.91]). Placebo was associated with the lowest risk of
withdrawal for AEs and had a 68.7% probability of
being the best treatment, with a SUCRA value of
0.875, follow by aztreonam with a 27.1% probability
of being the best treatment, with a SUCRA value of
0.79.DISCUSSION
LIS is a new formulation of levoﬂoxacin recently
approved in Europe for the treatment of chronic
pulmonary infection due to P aeruginosa in adult
patients with CF. The safety and efﬁcacy of LIS were
assessed in 2 Phase III RCTs. The studies compared
LIS with placebo and with TIS in patients with CF
aged Z12 years.8,10
In a multinational, randomized (2:1), double-blind
study comparing LIS with placebo in 330 patients
aged Z12 years with CF over a single cycle of
treatment (28 days on/28 days off), LIS did not
signiﬁcantly reduce protocol-deﬁned pulmonary exac-
erbations, which was the primary end point of the
study. However, LIS was associated with signiﬁcantly
higher relative change in FEV1% predicted from
baseline to day 28 than placebo, with a least squares
mean difference of 2.42 (95% CI, 0.53–4.30).30
In another Phase III study, LIS was compared with
TIS in a randomized, open-label, parallel-group, non-
inferiority study in 282 patients for 24 weeks.6 In this
study, the treatment cycle included 28 days of
treatment with LIS or TIS daily followed by 28 days
with inhaled antibiotics. The relative change in
FEV1% predicted from baseline to day 28 with LIS,
which was the primary end point, was noninferior to
TIS. Interestingly, in a categorical assessment of
FEV1% predicted, it was observed that 70% of
patients receiving LIS exhibited improvement in
relative change in FEV1% predicted from baseline to
day 28 compared with only 53% of patients receiving
TIS (P ¼ 0.03).
In both studies, patients had to receive at least three
28-day courses (484 days) of TIS over the past 12
months to be eligible for study enrollment. The
mandate of prior inhaled antibiotic use might have
selected a group of patients with CF who may be more20difﬁcult to manage and more likely not to respond
well to another course of therapy. The presence of
Staphylococcus aureus was noted in 450% of pa-
tients in both studies. The presence of other pathogens
may affect a patient’s response to inhaled antibiotics.
These observations are important to consider when
interpreting the ﬁndings of this NMA.
A previous NMA conducted by Littlewood et al3
did not include LIS and did not address any safety or
tolerability aspects of inhaled antibiotics when
treating chronic P aeruginosa lung infection in
patients with CF. The investigators concluded that
all inhaled antibiotics evaluated were comparable in
terms of efﬁcacy at 4 weeks as measured by change
from baseline in FEV1% predicted, P aeruginosa
sputum density, and acute pulmonary exacerbations.
With the recent approval of LIS for the treatment of
chronic P aeruginosa lung infection in adult patients
with CF, the relative efﬁcacy of all currently available
inhaled antibiotics must be determined to successfully
guide health care decision-making. The aims of the
present review focused on examining the clinical
evidence across a number of clinical end points to
assess efﬁcacy for the most widely used inhaled anti-
biotics for the management of chronic P aeruginosa
lung infection in patients with CF in a systematic
approach. We then compared the efﬁcacy of the most
widely used inhaled antibiotics for the management of
chronic P aeruginosa lung infection by using a
Bayesian mixed treatment comparison of RCTs. An
examination of study withdrawal rates (including
study withdrawals due to AEs) was performed.
Few RCTs of inhaled antibiotics meet the rigorous
inclusion and exclusion criteria for review. Although
12 months of follow-up is recommended by regula-
tory agencies, the majority of these RCTs had only 4
to 8 weeks of follow-up. We performed the NMA on
both short-term (4 weeks) and long-term (24 weeks)
efﬁcacy outcomes and anticipated that there would be
signiﬁcant heterogeneity across all trials.
The relative FEV1% predicted change from baseline
to 4 weeks seemed to be numerically highest with
aztreonam. The relative FEV1% predicted change from
baseline to 4 weeks with LIS was numerically higher
than with TIS, TIP, colistimethate sodium, and placebo,
but all the 95% Crls included zero. Similarly, the
relative FEV1% change from baseline to 24 weeks also
seemed to be numerically higher for LIS compared with
TIS, TIP, and aztreonam but not signiﬁcantly betterVolume ] Number ]
J.S. Elborn et al.than these comparators. At 24 weeks, LIS was found to
be signiﬁcantly better than placebo, which is consistent
with the ﬁndings from the 2 Phase III studies.
Although FEV1% is a well-recognized end point in
assessing efﬁcacy of inhaled antibiotics in patients
with CF, other clinical outcomes (eg, changes in
P aeruginosa sputum density, acute pulmonary exac-
erbation, hospitalization, additional antibiotics use)
should also be considered when assessing the efﬁcacy
of these inhaled antibiotics.
The NMA for P aeruginosa density change from
baseline to 4 weeks found that levoﬂoxacin had
signiﬁcantly better P aeruginosa sputum density im-
provement than placebo (mean change vs levoﬂoxa-
cin, 0.64), but both tobramycin formulations (TIS and
TIP) and aztreonam were found to be numerically
more effective than levoﬂoxacin at 4 weeks, although
probabilities of inferiority of levoﬂoxacin were
o95%. The NMA for P aeruginosa density change
from baseline to 24 weeks also found that both
tobramycin formulations were numerically more ef-
fective than levoﬂoxacin but were not signiﬁcant
because the 95% CrI included zero.
Acute pulmonary exacerbation is an important clinical
outcome, but there is no standard deﬁnition for acute
pulmonary exacerbation and no established guidelines on
how this should be measured in clinical trials. As
discussed earlier, one of the LIS Phase III clinical studies
did not meet the primary end point of superiority in the
time to pulmonary exacerbation compared with pla-
cebo.30 Thus, for the purpose of this NMA, we adopted
2 proxies for CF acute pulmonary exacerbations:
hospitalizations and additional antibiotic use.
For trials with 4 weeks of follow-up, an indirect
comparison was conducted for hospitalization instead
of NMA due to insufﬁcient trials being available.
Patients treated with aztreonam 75 mg BID were more
likely to be hospitalized than patients treated with
levoﬂoxacin. However, this trend was not observed in
patients treated with aztreonam 75 mg TID. In trials
with 24 weeks of follow-up, hospitalization was
reported in 4 trials with TIS and TIP, levoﬂoxacin,
and placebo. Patients treated with levoﬂoxacin were
signiﬁcantly less likely to be hospitalized compared
with placebo, TIP, and TIS. Because the deﬁnitions for
hospitalization varied across studies, these ﬁndings
should be interpreted with caution. There has been a
trend of managing acute pulmonary exacerbations at
home rather than at hospitals.] 2016Additional antibiotics use was reported in 5 trials
with 4 weeks of follow-up that were included in the
NMA.8–10,26,27 Compared with patients treated with
levoﬂoxacin, patients treated with TIS or who received
placebo required additional antibiotics. These ﬁndings
were comparable with the NMA conducted in trials
with 24 weeks of follow-up.6,23,26,28,29 The use of
levoﬂoxacin was associated with a numerically lower
probability of additional antibiotics use than the use
of TIS, TIP, and placebo. Similar to hospitalization,
the deﬁnitions for additional antibiotics use varied
between studies, and thus the results should be
interpreted with caution.
Because not all studies reported AEs, we could not
directly compare the safety proﬁles of these inhaled
antibiotics. Although study withdrawal rates were
examined, deﬁnitive conclusions about the relative
safety proﬁles of these inhaled antibiotics could not
be made. The study withdrawal rates due to any
reason and due to any AEs were analyzed in the NMA
by using trials with 24 weeks of follow-up. Compared
with LIS, there was a trend of higher probabilities of
study withdrawal for patients treated with colistime-
thate sodium, TIP, and placebo. A trend toward a
lower probability of withdrawal was found for
aztreonam and TIS compared with LIS.
Due to the limitations of the study design of each
trial, the heterogeneity of these studies, and the
variability of outcomes due to changes in clinical
practice over time, the results of this NMA should
be considered with caution. Additional evaluation
and/or further studies may be warranted. An open-
label study design is associated with risk of bias such
as performance and detection bias for outcomes and
study withdrawal. As such, the decision to withdraw
from an open-label or unblinded study may be
inﬂuenced by the physician or patient’s knowledge
of the treatment received. In addition, a patient’s
baseline characteristics such as prior antibiotic use
and presence of other pathogens could inﬂuence the
response to inhaled antibiotics. Because we excluded
studies that involved patients aged o6 years, our
ﬁndings cannot be extrapolated to patients in this
age group.
Due to the limited number of studies available for
inclusion, it was not possible to fully account for
heterogeneity among the studies included in the NMA.
Only ﬁxed effect models were constructed for the
NMA using trials with 24 weeks of follow-up.21
Clinical TherapeuticsBecause we were unable to construct random models
due to the small number of studies, the CrIs might not
have represented the full extent of uncertainty around
results. Additional research is therefore needed to
determine the impact of other potential effect modi-
ﬁers on outcomes and to assess their relative impor-
tance in inﬂuencing outcomes. The lack of signiﬁcant
evidence of this NMA does not imply that the inhaled
antibiotics evaluated were not different in terms of
efﬁcacy. A difference in efﬁcacy among these inhaled
antibiotics may be present, but due to the limited data
available for comparison, a signiﬁcant difference may
not have been observed. Thus, it is important to
interpret our ﬁndings with caution and consider other
clinical efﬁcacy outcomes when selecting an inhaled
antibiotic in treating pulmonary infection in patients
with CF.CONCLUSIONS
Based on this SLR and NMA, the analyses for many
of the outcomes evaluated did not provide signiﬁcant
evidence to indicate that the other inhaled antibiotics
were either more or less effective than LIS. Although
additional studies on each of these outcomes are
needed, there is a trend in favor of LIS for the relative
FEV1% change from baseline at 24 weeks and for
reducing the need of hospitalization. Because patients
with CF with chronic P aeruginosa infections fre-
quently require changes in treatment, the availability
of LIS provides a useful option to preserve respiratory
function over a longer period of time.ACKNOWLEDGMENTS
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